Table 2.
Observed malignant cancer cases by disease and period of observation (%)
| Disease | 1990–1994 | 1995–1999 | 2000–2004 | 2005–2009 | 2010–2014 |
|---|---|---|---|---|---|
| ALL | 210 (20.5) | 193 (18.8) | 205 (20.0) | 199 (19.4) | 217 (21.1) |
| LA hybrid/undiff. | 6 (50.0) | 4 (33.3) | 1 (8.3) | 1 (8.3) | 0 |
| ANLL | 39 (17.7) | 42 (19.0) | 40 (18.1) | 50 (22.7) | 49 (22.2) |
| MCL | 5 (20.8) | 3 (12.5) | 3 (12.5) | 4 (16.6) | 9 (37.5) |
| NHL | 52 (18.5) | 63 (22.4) | 59 (20.9) | 61 (21.7) | 46 (16.3) |
| HL | 16 (8.4) | 35 (18.5) | 35 (18.5) | 41 (21.6) | 62 (32.8) |
| Neuroblastoma | 75 (21.9) | 58 (16.9) | 67 (19.5) | 72 (21) | 70 (20.4) |
| CNS Tumour | 31 (6.2) | 78 (15.6) | 118 (23.6) | 122 (24.4) | 151 (30.5) |
| Kidney Tumour | 44 (21.7) | 45 (22.2) | 29 (14.3) | 39 (19.3) | 45 (22.2) |
| Soft tissue sarcoma | 31 (14.6) | 44 (20.7) | 45 (21.2) | 56 (26.4) | 36 (16.9) |
| Histiocytosis | 25 (14.8) | 27 (16.0) | 33 (19.6) | 47 (27.9) | 36 (21.4) |
| GCT | 15 (14.0) | 18 (16.8) | 12 (11.2) | 29 (27.1) | 33 (30.8) |
| S. Ewing/PNET | 14 (12.8) | 20 (18.3) | 22 (20.1) | 22 (20.1) | 31 (28.4) |
| Retinoblastoma | 16 (20.7) | 9 (11.6) | 22 (28.5) | 20 (25.9) | 10 (12.9) |
| Bone Tumour | 16 (25.3) | 12 (19.0) | 8 (12.6) | 14 (22.2) | 13 (20.6) |
| Liver Tumour | 6 (13.3) | 12 (26.6) | 9 (20.0) | 8 (17.7) | 10 (22.2) |
| Nasofaryngeal carcinoma | 3 (33.3) | 1 (11.1) | 2 (22.2) | 2 (22.2) | 1 (11.1) |
| Adrenocortical carcinoma | 3 (27.2) | 2 (18.1) | 3 (27.2) | 0 | 3 (27.2) |
| Other Tumours | 4 (6.6) | 7 (11.6) | 13 (21.6) | 19 (31.6) | 17 (28.3) |
| Total | 611 (16.7) | 673 (18.4) | 726 (19.8) | 806 (22) | 839 (22.9) |
ALL acute lymphoblastic leukemia, ANLL acute non lymphoblastic leukemia, MCL myeloid chronic leukemia, NHL non hodgkin lymphoma, HL hodgkin lymphoma, CNS central nervous system, GCT germ cell tumour, PNET peripheral neuroectodermal tumor